https://www.factcheckjoerogan.com An evidence log for the Joe Rogan Experience: every claim with timestamp, sources, and who benefits. en-us Tue, 07 Jul 2026 18:52:05 GMT https://www.factcheckjoerogan.com/claims/cmrb07n210020w16h9repal1l https://www.factcheckjoerogan.com/claims/cmrb07n210020w16h9repal1l Tue, 07 Jul 2026 18:51:13 GMT Howard asserted that cancer rates rose 300%, all-cause mortality rose 40% in some age groups, and pulmonary embolisms rose nearly 500%, framed as consequences of covid-19 vaccination. National vital statistics do not support these figures. CDC/NCHS data on U.S. mortality in 2023 show age-specific death rates decreased, not increased, for every age group 5 years and older compared with 2022, and the overall age-adjusted death rate fell 6.0% (from 798.8 to 750.5 per 100,000), while life expectancy rose to 78.4 years. No CDC, NCI/SEER, or peer-reviewed national dataset shows a 300% rise in cancer incidence or a 40% rise in mortality for any age group coinciding with the vaccine rollout; annual cancer incidence and mortality statistics tracked by the American Cancer Society show gradual, low single-digit percentage shifts per year for most cancer types, not hundreds of percent. Pulmonary embolism incidence has risen modestly over recent decades, largely attributed to improved imaging detection, but no population-level dataset documents a near-500% surge tied to vaccination. As stated, the claim is not supported by, and is directly contradicted by, the best available national mortality and cancer statistics. https://www.factcheckjoerogan.com/claims/cmrb07mr6001ow16hfftcha71 https://www.factcheckjoerogan.com/claims/cmrb07mr6001ow16hfftcha71 Tue, 07 Jul 2026 18:51:13 GMT Howard's claim traces back to a single 2021 in vitro study (Jiang & Mei, published in Viruses) reporting that SARS-CoV-2 spike protein localized to the nucleus and suppressed BRCA1 and other DNA-repair proteins in cultured, plasmid-transfected cells. That study did not test vaccination, did not involve mRNA vaccines, and used spike protein overexpression in a dish rather than physiological exposure in humans. The paper drew an expression of concern from the publisher in December 2021 and was formally retracted in May 2022 after independent reviewers found its methodology and conclusions unsound. No peer-reviewed research has since established that COVID-19 vaccination silences BRCA1 or causes cancer in humans, and mRNA vaccines do not enter the cell nucleus or alter DNA. The specific mechanism Howard describes is not supported by current evidence, and its original scientific basis has been withdrawn from the literature. https://www.factcheckjoerogan.com/claims/cmrazy197001h6l6hil9e6ui0 https://www.factcheckjoerogan.com/claims/cmrazy197001h6l6hil9e6ui0 Tue, 07 Jul 2026 18:44:16 GMT Carlson claims the fossil record contains no transitional chain documenting common descent and that Darwinian evolution remains unproven, still "just a theory" nearly 200 years after Darwin. The fossil record contains numerous documented transitional forms; a prominent example is Tiktaalik roseae, described in Nature in 2006, a Late Devonian (~375-million-year-old) fish with intermediate fish-and-tetrapod features that illustrates the water-to-land transition. In science, a "theory" is a well-substantiated explanation of the natural world supported by extensive evidence, not an unproven guess, so a claim remaining "a theory" does not indicate weakness or lack of proof. The assertion that no transitional fossils exist is contradicted by the documented fossil record, and the "just a theory" framing misstates scientific terminology. https://www.factcheckjoerogan.com/claims/cmrazy15h001c6l6he78gizgm https://www.factcheckjoerogan.com/claims/cmrazy15h001c6l6he78gizgm Tue, 07 Jul 2026 18:44:16 GMT Carlson asserts there is and has never been any evidence that objects enter Earth's atmosphere from another planet, and reframes unidentified anomalous phenomena (UAP) as spiritual or supernatural phenomena native to Earth. The narrower factual claim is broadly consistent with official findings: NASA's Unidentified Anomalous Phenomena Independent Study Team concluded in its September 2023 final report that there is 'no conclusive evidence suggesting an extraterrestrial origin for UAP,' and the Pentagon's All-domain Anomaly Resolution Office (AARO) found in its March 2024 Historical Record Report that it has no verifiable evidence the U.S. government possesses or has reverse-engineered extraterrestrial technology, with the vast majority of sightings attributed to ordinary objects such as drones, balloons, and aircraft. However, the framing is misleading in two respects: NASA explicitly treats extraterrestrial origin as an unresolved, still-open scientific question rather than a settled impossibility, and investigators attribute the absence of a conclusion primarily to poor-quality data rather than to disproof. Carlson's substitute explanation, that UAPs are supernatural or spiritual entities, has no evidentiary support in the scientific or investigative record and is not falsifiable. Overall status: misleading, because it presents an open, data-limited question as settled and offers an unsupported alternative in place of the extraterrestrial hypothesis it dismisses. https://www.factcheckjoerogan.com/claims/cmrazy0vk00136l6hh3e8bdg4 https://www.factcheckjoerogan.com/claims/cmrazy0vk00136l6hh3e8bdg4 Tue, 07 Jul 2026 18:44:16 GMT Kennedy claimed that not one of the 72 vaccines on the U.S. childhood schedule has ever been tested pre-licensure against a true placebo, comparing vaccinated to unvaccinated children on health outcomes. FDA licensing records and peer-reviewed publications document at least one clear counterexample: the rotavirus vaccine RotaTeq was evaluated pre-licensure in 3 placebo-controlled clinical trials totaling 71,725 infants (36,165 vaccine recipients vs. 35,560 placebo recipients), with parents/guardians contacted after each dose to track intussusception, other serious adverse events, and deaths as outcomes, per RotaTeq's FDA-approved prescribing information. A separate large randomized, double-blind, placebo-controlled trial of another rotavirus vaccine (Ruiz-Palacios et al., New England Journal of Medicine, 2006) enrolled 63,225 infants roughly split between vaccine and placebo arms and measured severe gastroenteritis, hospitalization, and intussusception as health outcomes. Because Kennedy's claim is an absolute ('not one... ever'), even one documented pre-licensure placebo-controlled trial with health outcomes is sufficient to make the claim as stated false, regardless of how the broader vaccine schedule's testing history is characterized. https://www.factcheckjoerogan.com/claims/cmrazy0s8000y6l6hvo52cvtw https://www.factcheckjoerogan.com/claims/cmrazy0s8000y6l6hvo52cvtw Tue, 07 Jul 2026 18:44:16 GMT Whole-cell DTP vaccine was used in the United States from the 1940s through the 1990s; U.S. health authorities (the Institute of Medicine, per CDC/ACIP) did conclude the whole-cell pertussis component was causally linked to rare acute encephalopathy, and CDC confirms no whole-cell DTP vaccine is currently licensed in the U.S., having been fully replaced by the acellular DTaP vaccine in the 1990s because of safety concerns. However, the transition was a phased shift to a lower-reactogenicity product as it became available, not a recall or ban triggered by a documented 1-in-300 death/brain-damage rate; that specific ratio does not appear in CDC, WHO, or peer-reviewed estimates of serious whole-cell DTP adverse events. CDC's own cited postlicensure surveillance (Japan, 1970-1974) found acute encephalopathy/encephalitis (including deaths) at a rate of about 7.6 cases per 10 million doses under whole-cell DTP, roughly 1 in 1.3 million, several orders of magnitude rarer than 1 in 300. Whole-cell DTP-containing vaccines remain WHO-prequalified and are still used in many low- and middle-income countries, including through Gavi, the Vaccine Alliance (which the Gates Foundation helps fund), because international health bodies continue to judge their benefit-risk profile favorable given pertussis's high fatality risk in unvaccinated infants; this reflects ongoing global vaccine policy, not a product banned for a proven safety reason and then covertly redirected to Africa. The claim mixes an accurate underlying fact (the U.S. did move away from whole-cell DTP) with a fabricated injury rate and an inaccurate characterization of why and how the transition occurred and of current WHO/Gavi-supported immunization programs. https://www.factcheckjoerogan.com/claims/cmrazy0nh000t6l6h4av0xk5k https://www.factcheckjoerogan.com/claims/cmrazy0nh000t6l6h4av0xk5k Tue, 07 Jul 2026 18:44:16 GMT A 2005 laboratory study (Vincent et al., Virology Journal) found that chloroquine strongly inhibited SARS-CoV-1 infection and spread in primate (Vero E6) cell cultures, with antiviral effects observed when cells were treated either before or after exposure to the virus. This was an in-vitro cell-culture finding, not a clinical trial in humans; the 2003 SARS outbreak subsided before any randomized controlled trial could test chloroquine or hydroxychloroquine against SARS-CoV-1 disease in patients, so no such clinical evidence exists. The study's own conclusion describes chloroquine as effective 'in cell culture,' not as proven clinical therapy. This lab finding was later invoked during the COVID-19 pandemic to argue hydroxychloroquine should work against SARS-CoV-2, but large randomized trials, including the WHO Solidarity trial, found that hydroxychloroquine produced little or no reduction in mortality among hospitalized COVID-19 patients, leading WHO to discontinue that treatment arm in July 2020. Describing hydroxychloroquine as 'known to be effective' against SARS-1 therefore overstates a preliminary cell-culture result as established clinical fact. https://www.factcheckjoerogan.com/claims/cmrazy0kc000p6l6h6sbphkh7 https://www.factcheckjoerogan.com/claims/cmrazy0kc000p6l6h6sbphkh7 Tue, 07 Jul 2026 18:44:16 GMT Malone is referencing Gazit et al., a retrospective cohort study from Israel's Maccabi Healthcare Services (posted as a preprint in August 2021 and later peer-reviewed and published in Clinical Infectious Diseases in 2022), which compared previously infected, unvaccinated people to vaccinated, previously uninfected people during a Delta-variant period in mid-2021. The study's own abstract states its population as 124,500 persons, not 2.5 million as Malone states. The 13.06-fold, 5.96-fold, and 27.02-fold figures reported in the study measured the risk of breakthrough infection or symptomatic disease, not hospitalization; the study explicitly reports that COVID-19-related hospitalizations were too few in number (single digits to low teens in each comparison arm) to allow a statistically significant comparison, and it does not report a '6-13x' or '27-fold' figure for hospitalization prevention specifically. As an observational study, it was also subject to confounders such as differing timing of infection versus vaccination and differential healthcare-seeking or testing behavior between groups, which the authors partially addressed with sensitivity analyses. A CDC-led case-control analysis from Kentucky published the same month found that vaccination provided added protection against reinfection even among the previously infected, indicating the relative-protection picture is more mixed than a single large multiplier implies. The specific hospitalization-effectiveness figures Malone cites are not supported by the cited study's actual reported results. https://www.factcheckjoerogan.com/claims/cmrazy0go000l6l6hqcnaociz https://www.factcheckjoerogan.com/claims/cmrazy0go000l6l6hqcnaociz Tue, 07 Jul 2026 18:44:16 GMT Malone claimed Omicron's mortality was "remarkably low" and "essentially like a cold." Peer-reviewed evidence confirms Omicron was substantially less severe per infection than the Delta variant: a large UK national cohort study (The Lancet, 2022) found an adjusted hazard ratio for death of 0.31 for Omicron versus Delta, meaning roughly a two-thirds lower risk of death per case, with a similar reduction (HR 0.41) in hospital admission risk. This risk reduction also varied by age: the hospitalization-risk reduction was smaller in adults 80 and older (HR 0.47) than in 60-69 year-olds (HR 0.25), showing the severity drop was less pronounced in the oldest patients. Separately, CDC surveillance of the U.S. Omicron wave (through mid-January 2022) found that even though the highest 7-day average of daily deaths during that period (1,854) was actually lower than in prior high-transmission periods, the report describes the average daily death count during the Omicron surge as remaining "substantial," alongside record numbers of cases, ED visits, and hospital admissions that strained the health system. Together, these sources support that Omicron caused meaningfully fewer deaths and hospitalizations per infection than Delta, but they do not support equating Omicron's mortality with that of a common cold: the CDC data show a still-substantial, non-trivial daily death toll during the surge, and reduced per-case severity was not uniform across all groups. The claim is best characterized as misleading: it accurately reflects a real, well-documented reduction in per-infection severity relative to Delta, but overstates that reduction into a false equivalence with a common cold's near-zero mortality. https://www.factcheckjoerogan.com/claims/cmrazy0yu00176l6hn8ovb8fi https://www.factcheckjoerogan.com/claims/cmrazy0yu00176l6hn8ovb8fi Tue, 07 Jul 2026 18:44:16 GMT Kennedy's claim that almost half of the FDA's budget comes from pharmaceutical companies refers to industry-paid user fees authorized under laws like the Prescription Drug User Fee Act (PDUFA), and the figure is broadly consistent with government data. A 2023 HHS/ASPE issue brief found that in fiscal year 2022, user fees accounted for 46% ($2.9 billion) of FDA's total budget of $6.2 billion, with the share varying by program (66% of the human drugs program budget, 43% for biologics, 35% for medical devices). FDA's own public explainer confirms that user fees supplement congressional appropriations, can legally be spent only on the specified review and safety activities Congress designates, and that approval decisions are made based on science rather than tied to fee payment. So "almost 50%" is a reasonable approximation of the total-agency figure, though the share is considerably higher for the drug-review programs specifically. Whether this funding structure amounts to regulatory "capture" is a matter of ongoing debate among health-policy researchers rather than a settled empirical fact. https://www.factcheckjoerogan.com/claims/cmrazy0di000h6l6h9cxkkjv3 https://www.factcheckjoerogan.com/claims/cmrazy0di000h6l6h9cxkkjv3 Tue, 07 Jul 2026 18:44:16 GMT Malone stated that myocarditis requiring hospitalization after mRNA COVID-19 vaccination occurs in about 1 in 2,700 recipients. CDC's VAERS-based surveillance, presented to the Advisory Committee on Immunization Practices in June 2021, found myocarditis reporting rates after a second mRNA dose of 62.8 per million in males aged 12-17 (about 1 in 15,900); a subsequent peer-reviewed CDC/FDA analysis published in JAMA (Oster et al., 2022) refined this to 70.7 per million second doses in males 12-15 and 105.9 per million in males 16-17 (roughly 1 in 9,400 to 1 in 14,100). That same JAMA analysis found about 96% of the reported myocarditis cases among people under 30 were hospitalized, mostly for monitoring, with 87% resolving symptoms by discharge, so the hospitalization-specific rate tracks closely with the overall myocarditis rate rather than being a separate, much smaller figure. Across the age and sex strata studied, no published surveillance estimate approaches a rate as high as 1 in 2,700; the best-supported figures for adolescent males are roughly three to five times rarer than the number cited. The claim therefore overstates the frequency of hospitalization-requiring vaccine-associated myocarditis relative to current CDC and peer-reviewed evidence. https://www.factcheckjoerogan.com/claims/cmrazy08t000b6l6ha6p7q1j5 https://www.factcheckjoerogan.com/claims/cmrazy08t000b6l6ha6p7q1j5 Tue, 07 Jul 2026 18:44:16 GMT McCullough contrasted a sub-1% COVID-19 case fatality figure with vaccine recipients who "died or got myocarditis," implying a comparable scale of harm from vaccination. CDC's national passive-surveillance system (VAERS) explicitly states that a report of death or illness following vaccination does not, by itself, establish that the vaccine caused the event, since anyone can submit a VAERS report regardless of cause. CDC's own review of confirmed myocarditis cases found about 1,226 VAERS reports of myocarditis following mRNA vaccination out of roughly 296 million doses administered through mid-2021, a rate several orders of magnitude smaller than the population-wide scale implied by comparing it to overall infection outcomes; the condition was rare, occurred predominantly in young males after a second dose, and was typically mild and resolved with care. A large prospective safety-surveillance study of over 10 million vaccine-eligible people in the Vaccine Safety Datalink found no statistically significant increase in serious adverse outcomes, including cardiac events, in the 21 days after mRNA vaccination compared with a later comparison window. Current evidence characterizes vaccine-associated death as exceedingly rare and myocarditis as an uncommon, mostly mild, age- and sex-stratified risk, not a mortality or injury burden approaching the scale of COVID-19's fatality toll as the quote implies. https://www.factcheckjoerogan.com/claims/cmrazy05b00066l6hzp4zw29d https://www.factcheckjoerogan.com/claims/cmrazy05b00066l6hzp4zw29d Tue, 07 Jul 2026 18:44:16 GMT Large, randomized controlled trials found hydroxychloroquine ineffective against COVID-19. The UK RECOVERY trial, one of the largest randomized trials of hospitalized COVID-19 patients, found no significant difference in 28-day mortality between hydroxychloroquine and usual care (27.0% vs. 25.0%) and closed its hydroxychloroquine arm early after an interim analysis found a lack of efficacy. The WHO's Solidarity trial similarly found hydroxychloroquine produced little or no reduction in mortality among hospitalized COVID-19 patients compared to standard of care, leading WHO to discontinue the treatment arm in July 2020. The FDA has warned against using hydroxychloroquine or chloroquine for COVID-19 outside a hospital or clinical trial due to the risk of heart rhythm problems. These major trials focused on hospitalized patients rather than early outpatient treatment, so they do not directly refute a claim about early-treatment efficacy specifically. The '64% efficacy' figure McCullough cites traces to aggregation websites that pool large numbers of small, often non-randomized or non-peer-reviewed studies with methodological weaknesses, rather than to a peer-reviewed meta-analysis of high-quality randomized trials; such aggregated figures are not endorsed by regulatory agencies or major medical journals. The scientific and regulatory consensus, based on the largest and most rigorous trials available, is that hydroxychloroquine does not provide meaningful benefit for COVID-19 treatment and carries cardiac risks. https://www.factcheckjoerogan.com/claims/cmrazy01h00026l6h6xa73c40 https://www.factcheckjoerogan.com/claims/cmrazy01h00026l6h6xa73c40 Tue, 07 Jul 2026 18:44:16 GMT McCullough was likely referencing his own paper, "Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection," published online in the American Journal of Medicine in early August 2020 (indexed as Epub 2020 Aug 7). However, the peer-reviewed literature already contained proposals for combining repurposed drugs in early outpatient COVID-19 treatment before that date. Harvey Risch's paper, "Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis," was published online in the American Journal of Epidemiology on May 27, 2020 (CrossRef record created May 23, 2020), roughly two and a half months before McCullough's paper, and explicitly argued for combination outpatient treatment with hydroxychloroquine plus azithromycin in high-risk patients. This directly contradicts the claim that no prior peer-reviewed paper had proposed a multidrug outpatient treatment approach. The specific figures of 55,000 total papers and 4,000 drug-related papers are not independently verifiable and appear to be rough, unsourced estimates rather than a documented literature count. https://www.factcheckjoerogan.com/claims/cmrayo3wl0002ar6hqniu4dw8 https://www.factcheckjoerogan.com/claims/cmrayo3wl0002ar6hqniu4dw8 Tue, 07 Jul 2026 18:07:16 GMT The Tuskegee study was real and is one of the most notorious ethics violations in U.S. medical history, but several specifics here are wrong. Participants were not injected with syphilis: the roughly 600 Black men enrolled in 1932 either already had latent syphilis or were uninfected controls, and the abuse was that researchers deliberately withheld effective treatment, penicillin, the standard cure from the late 1940s, so they could observe the untreated disease. The study ran about 40 years, from 1932 until it was exposed and halted in 1972, not 60 years, and it began in 1932, not the early 1920s. The CDC, which names it 'The Untreated Syphilis Study at Tuskegee,' documents that the men were misled about treatment but were not deliberately infected.